NASDAQ:SNOA Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis $1.14 -0.04 (-2.97%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sonoma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.12▼$1.1650-Day Range$1.04▼$2.9352-Week Range$0.85▼$6.92Volume62,411 shsAverage Volume116,593 shsMarket Capitalization$1.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Sonoma Pharmaceuticals, Inc. is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options. At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases. This approach is designed to enhance efficacy while minimizing skin irritation. The company’s lead product, Azclear® Foaming Gel, leverages azelaic acid to address papulopustular rosacea, and is complemented by additional prescription formulations and a suite of over-the-counter cleansers and medicated washes targeting acne-prone skin. Headquartered in Santa Rosa, California, Sonoma Pharmaceuticals distributes its dermatology portfolio through physician offices, retail pharmacies and online channels across the United States. Under the leadership of President and Chief Executive Officer Mark D. Sirgo, the company is advancing its clinical pipeline and exploring strategic collaborations to expand its product offerings and reach new patient populations.AI Generated. May Contain Errors. Read More Sonoma Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreSNOA MarketRank™: Sonoma Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Sonoma Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sonoma Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sonoma Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSonoma Pharmaceuticals has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sonoma Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.23% of the float of Sonoma Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sonoma Pharmaceuticals has recently decreased by 58.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSonoma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSonoma Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders24.59% of the stock of Sonoma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.Read more about Sonoma Pharmaceuticals' insider trading history. Receive SNOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNOA Stock News HeadlinesWhat's going on with Sonoma Pharma stock Monday?April 27, 2026 | msn.comSonoma Pharmaceuticals Announces Pricing of $4 Million Public OfferingApril 25, 2026 | finance.yahoo.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.May 8 at 1:00 AM | Profits Run (Ad)Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and WalmartMarch 24, 2026 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial ResultsFebruary 10, 2026 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product DevelopmentJanuary 29, 2026 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedNovember 14, 2025 | finanznachrichten.deSonoma Pharmaceuticals’ Reliefacyn Advanced receives NRS Seal of AcceptanceNovember 13, 2025 | msn.comSee More Headlines SNOA Stock Analysis - Frequently Asked Questions How have SNOA shares performed this year? Sonoma Pharmaceuticals' stock was trading at $3.64 at the start of the year. Since then, SNOA stock has decreased by 68.7% and is now trading at $1.1410. How were Sonoma Pharmaceuticals' earnings last quarter? Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) issued its quarterly earnings data on Tuesday, February, 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.06. The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $5.47 million. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 42.56% and a negative net margin of 19.04%. How do I buy shares of Sonoma Pharmaceuticals? Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sonoma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Meta Platforms (META), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Ford Motor (F) and PayPal (PYPL). Company Calendar Last Earnings2/10/2026Today5/08/2026Next Earnings (Estimated)7/15/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, SNOA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNOA CIK1367083 Webwww.sonomapharma.com Phone(800) 759-9305Fax707-283-0551Employees180Year Founded1999Profitability EPS (Trailing Twelve Months)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.46 million Net Margins-19.04% Pretax Margin-19.47% Return on Equity-42.56% Return on Assets-11.97% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.00 Sales & Book Value Annual Sales$17.72 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.42Miscellaneous Outstanding Shares1,731,000Free Float1,305,000Market Cap$1.98 million OptionableNot Optionable Beta1.28 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SNOA) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMay 13: The Fed Shock is about to hit the marketsWall Street quantitative analyst Louis Navellier says a rare Federal Reserve regime change is opening a market...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
